AVTX Stock Analysis: Buy, Sell, or Hold?
AVTX - Avalo Therapeutics, Inc. Common Stock
$18.84
1.55 (8.96%)
▲
5d:
+4.67%
30d:
+34.96%
90d:
+12.81%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When AVTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AVTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AVTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AVTX is currently trading at $18.84, which is considered extended relative to its 30-day fair value range of $13.68 to $17.68.
Technical Outlook: Technically, AVTX is showing sideways momentum. Immediate support is located at $14.59, while resistance sits at $20.10. The stock is showing strong short-term momentum, up 9.0% recently.
Market Sentiment: AVTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.25 (+140.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AVTX is showing sideways momentum. Immediate support is located at $14.59, while resistance sits at $20.10. The stock is showing strong short-term momentum, up 9.0% recently.
Market Sentiment: AVTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.25 (+140.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.68 -
$17.68
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+6.6% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.0%)
- BULLISH: Trading 140.2% below Wall St target ($45.25)
Trading Range Analysis
30-Day Trading Range
$13.68 -
$17.68
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$14.59
Resistance Level
$20.10
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.73
Wall Street Target
$45.25
(+140.2%)
Revenue Growth (YoY)
-69.3%
Share & Embed Analysis
Last updated: July 02, 2026 10:40 PM ET
Data refreshes hourly during market hours. Next update: 11:40 PM
Data refreshes hourly during market hours. Next update: 11:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Mittie Doyle
SELL
3970 shares
2026-04-06
Christopher Ryan Sullivan
SELL
7980 shares
2026-04-02
Christopher Ryan Sullivan
SELL
7979 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
